Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells), CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells)
Bristol-Myers Squibb Pharma EEIG
L01
lisocabtagene maraleucel
Antineoplastic agents
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Mediastinal Neoplasms
Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Revision: 2
Authorised
2022-04-04
52 B. PACKAGE LEAFLET 53 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT BREYANZI 1.1-70 × 10 6 CELLS/ML / 1.1-70 × 10 6 CELLS/ML DISPERSION FOR INFUSION lisocabtagene maraleucel (chimeric antigen receptor [CAR] positive viable T cells) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • Your doctor will give you a Patient card. Read it carefully and follow the instructions on it. • Always show the Patient card to the doctor or nurse when you see them or if you go into hospital. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Breyanzi is and what it is used for 2. What you need to know before you are given Breyanzi 3. How Breyanzi is given 4. Possible side effects 5. How to store Breyanzi 6. Contents of the pack and other information 1. WHAT BREYANZI IS AND WHAT IT IS USED FOR WHAT BREYANZI IS Breyanzi contains the active substance lisocabtagene maraleucel, a type of treatment called ‘genetically modified cell therapy’. Breyanzi is made from your own white blood cells.This involves taking some of your blood and separating out the white blood cells and sending the white blood cells to a laboratory so that they can be modified to make Breyanzi. WHAT BREYANZI IS USED FOR Breyanzi is used to treat adults with a type of blood cancer called lymphoma which affects your lymph tissue and causes white blood cells to grow out of control. Breyanzi is used for: • diffuse large B-cell lymphoma • high-grade B-cell lymphoma • primary mediastinal large B-cell lymphoma • follicu Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Breyanzi 1.1-70 × 10 6 cells/mL / 1.1-70 × 10 6 cells/mL dispersion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 GENERAL DESCRIPTION Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ and CD4+ T cells, in a defined composition, that have been separately transduced _ex vivo_ using a replication incompetent lentiviral vector expressing an anti- CD19 chimeric antigen receptor (CAR) comprising a single chain variable fragment (scFv) binding domain derived from a murine CD19-specific monoclonal antibody (mAb; FMC63) and a portion of the 4-1BB co-stimulatory endodomain and CD3 zeta (ζ) chain signalling domains and a nonfunctional truncated epidermal growth factor receptor (EGFRt). 2.2 QUALITATIVE AND QUANTITATIVE COMPOSITION Breyanzi contains CAR-positive viable T cells, consisting of a defined composition of CD8+ and CD4+ cell components: CD8+ cell component Each vial contains lisocabtagene maraleucel at a batch-specific concentration of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR-positive viable T cells). The medicinal product is packaged in one or more vials containing a cell dispersion of 5.1-322 × 10 6 CAR-positive viable T cells (1.1-70 × 10 6 CAR-positive viable T cells/mL) suspended in a cryopreservative solution. Each vial contains 4.6 mL of CD8+ cell component. CD4+ cell component Each vial contains lisocabtagene maraleucel at a batch-specific concentration of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR-positive viable T cells). The medicinal product is packaged in one or more vials c Lue koko asiakirja